Investor interest in company's with obesity candidates in their pipeline clearly remains high, given that a brand new ...

Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...

Braman Motors' lawyers believe their client is the first ERISA plan sponsor to join a big group of plaintiffs with cases ...

Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) and keeping the price ...

Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug ...

Also, Penn settled a lawsuit with the German drug manufacturer BioNTech, which, with Pfizer, made the COVID vaccine using ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/97.B9uuF-Zi.js ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) on January 6 and set a price ...

The Amphastar Pharmaceuticals' logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene MIST ®, Amphadase ®, Cortrosyn ®, REXTOVY ® and ...

The new name draws from the company’s nearly two decades of work in ryanodine receptor (RyR) biology, which it has used to ...

OTC Pharmaceuticals Consumption Projected to Grow Significantly, Germany Set to Lead Pharmaceuticals ProductionDublin, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The "Europe Healthcare Cold Chain Logistics - ...